Clinical Trial Update: A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of MP-101 in dementia-related psychosis and agitation/aggression was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Dementia
• Dementia
• Psychosis

Drugs mentioned

• MP-101

Snippet

Sponsor: Mediti Pharma Inc. | Conditions: Psychosis, Dementia | Phase 2 | Status: TERMINATED | Results posted: 2021-04-01